文献速递静脉血栓栓塞

预防剂量利伐沙班与华法林治疗孤立性小腿肌间静脉血栓的比较:回顾性倾向评分匹配分析

Prophylactic Dose of Rivaroxaban Versus Warfarin for the Treatment of Isolated Calf Muscle Vein Thrombosis: A Retrospective Propensity Score-Matched Analysis.
PubMed 文献 · Ann Vasc Surg · 2024-07-16

本研究回顾性分析472例孤立性小腿肌间静脉血栓(ICMVT)患者,比较预防剂量利伐沙班与华法林治疗的短期结局。倾向评分匹配后每组156例,两组静脉血栓栓塞事件和临床相关非大出血事件无显著差异,但利伐沙班组3个月血栓完全溶解率较低(51.3% vs 64.1%,P=0.022)。

要点

  • 倾向评分匹配后,利伐沙班组与华法林组静脉血栓栓塞事件无显著差异(9.0% vs 6.4%,P=0.395)。
  • 两组均无大出血事件,临床相关非大出血事件无显著差异(3.2% vs 6.4%,P=0.186)。
  • 利伐沙班组3个月血栓完全溶解率低于华法林组(51.3% vs 64.1%,P=0.022)。

核心结论

  • 在接受预防剂量利伐沙班或华法林治疗的ICMVT患者中,静脉血栓栓塞事件和出血事件无显著差异,但利伐沙班不利于血栓完全溶解。

研究设计与样本

  • 回顾性分析纳入472例接受两种不同治疗方案的ICMVT患者,采用倾向评分匹配平衡基线临床资料的混杂效应,匹配后每组156例。

主要发现

  • 匹配后,静脉血栓栓塞事件在利伐沙班组14例(9.0%)vs 华法林组10例(6.4%),P=0.395。
  • 匹配后,临床相关非大出血事件在利伐沙班组5例(3.2%)vs 华法林组10例(6.4%),P=0.186;两组均无大出血事件。
  • 匹配后,3个月血栓完全溶解在利伐沙班组80例(51.3%)vs 华法林组100例(64.1%),P=0.022。
  • 逻辑回归分析显示,利伐沙班组与华法林组在静脉血栓栓塞事件(比值比1.439,95%置信区间0.619-3.347,P=0.397)和临床相关非大出血事件(比值比0.483,95%置信区间0.161-1.449,P=0.194)方面无显著差异;3个月血栓完全溶解率两组不同(比值比0.589,95%置信区间0.375-0.928,P=0.022)。
  • 治疗 regimen(预防剂量利伐沙班)、血栓(最大直径>7 mm)和静脉血栓栓塞危险因素(非手术危险因素,主要指活动性恶性肿瘤)是ICMVT血栓不完全溶解的危险因素(P<0.05)。

关键数值与推荐

  • 预防剂量利伐沙班与华法林(总体INR>2.0的时间>50%)治疗ICMVT,短期随访中静脉血栓栓塞和出血事件无显著差异,但利伐沙班不利于血栓完全溶解。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 本研究为回顾性研究,随访时间短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prophylactic dose of rivaroxaban is often used in treatment of isolated calf muscle vein thrombosis (ICMVT); nevertheless, its effect is less reported. This study aims to evaluate short-term outcomes in patients with ICMVT who received prophylactic dose of rivaroxaban or warfarin therapy. METHODS: A retrospective analysis of 472 ICMVT patients who received 2 different treatment regimens was undertaken. Propensity score matching method was used to balance the confounding effect of baseline clinical data. Chi-squared test and logistic regression analysis were used to compare outcomes (venous thromboembolism events, bleeding events, complete clot resolution) according to the type of treatment regimens before and after propensity score matching. Univariate and multivariable analysis were used to investigate risk factors for incomplete clot resolution of ICMVT after propensity score matching. RESULTS: 242 ICMVT patients received prophylactic dose of rivaroxaban (rivaroxaban group, RG), and 230 received warfarin (warfarin group, WG). After propensity score matching, 156 patients were included in each group; Venous thromboembolism (VTE) events occurred in 14 (9.0%) patients in the RG and 10 (6.4%) in the WG (P = 0.395); no major bleeding events occurred in each group, and clinically relevant nonmajor bleeding events occurred in 5 (3.2%) patients in the RG and 10 (6.4%) in the WG (P = 0.186); complete clot resolution at 3 months occurred in 80 (51.3%) patients in the RG and 100 (64.1%) in the WG (P = 0.022). Logistic regression analysis showed that there were no significant differences between RG and WG in VTE events (odds ratio 1.439, 95% confidence interval 0.619-3.347, P = 0.397) and clinically relevant nonmajor bleeding events (odds ratio 0.483, 95% confidence interval 0.161-1.449, P = 0.194); it revealed that complete clot resolution rate at 3 months was different in the 2 groups (odds ratio 0.589, 95% confidence interval 0.375-0.928, P = 0.022). Treatment regimens (prophylactic dose of rivaroxaban), thrombosis (maximum diameter >7 mm), and risk factors for VTE (nonsurgery risk factors, mainly referring to active malignancy) were risk factors for incomplete clot resolution of ICMVT (P < 0.05). CONCLUSIONS: In this retrospective study with a short-term follow-up, ICMVT patients who received prophylactic dose of rivaroxaban had no significant differences in VTE and bleeding events compared to those who received warfarin therapy (the overall INR >2.0 for >50% of the time); but it was not conducive to complete clot resolution.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Qiu YH, Yang Z, Yang FJ, et al. Prophylactic Dose of Rivaroxaban Versus Warfarin for the Treatment of Isolated Calf Muscle Vein Thrombosis: A Retrospective Propensity Score-Matched Analysis. Ann Vasc Surg. 2024. PMID: 39025209. doi:10.1016/j.avsg.2024.06.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。